According to the latest clinical data, the personalized mRNA vaccine developed by Moderna and Merck reduces the risk of melanoma recurrence by 42 percent, marking a historic breakthrough in cancer research. #rákkutatás #melanoma #vakcina (translated)
Moderna and Merck's joint mRNA vaccine against skin cancer reduced the risk of recurrence and death from melanoma by 42% compared to traditional treatments in phase 3 clinical trials. #bőrrák #mRNSvakcina #technológia (translated)
The world's first cancer vaccine may soon be on the market, which reduced the risk of mortality and disease recurrence by 42% in melanoma patients during phase 3 clinical trials. #rák #vakcina #melanóma (translated)
A personalized therapeutic vaccine based on mRNA technology has been shown to reduce the risk of recurrence in melanoma by 42%, combined with immunotherapy, according to the results of the phase 3 INTerpath-001 study presented at the Congress of the European Society for Medical Oncology. #VaccinoPersonalizzato #Melanoma #mRna (translated)
The author wrote that Moderna, the company producing the Covid-19 vaccine, was preparing to obtain approval for a melanoma vaccine. He reported that the company had submitted a study on 1,100 patients that day, who were operated on to remove the tumor and treated with Keytruda. The post ended before the author completed the description of the treatment. (translated)
A new personalized mRNA vaccine against melanoma has been shown to reduce the risk of recurrence by 42% after two years, while still awaiting approval from regulatory authorities. #Vaccino #Melanoma #Immunoterapia (translated)
A new personalized vaccine against melanoma, Intismeran autogene, has been shown to significantly reduce the risk of recurrence and metastasis in patients undergoing combined treatment with immunotherapy, as highlighted by the INTerpath-001 study presented at the ESMO congress in Madrid. #VaccinoMelanoma #Immunoterapia #ESMO2026 (translated)
A new pill, HBI-8000, shows to expose advanced melanoma, significantly improving the effectiveness of immunotherapy and increasing patient survival without disease progression. #Immunoterapia #Melanoma #RicercaMedica (translated)
Moderna has presented its new, promising cancer vaccine, which reduced the recurrence of melanoma by 42% during the first major clinical trial, but it is still unknown how effective it will be for other types of cancer. #rákellenesvakcina #Moderna #mRNS (translated)
A personalized mRNA vaccine has been shown to reduce the risk of recurrence or death by 42% in high-risk melanoma patients who have already been operated on, according to an international clinical study. #Melanoma #Vaccini #Immunoterapia (translated)
A new molecule, HBI-8000, has shown to reduce the risk of progression of advanced melanoma by 27% and increase the percentage of patients with tumor regression when combined with the standard immunotherapy treatment nivolumab. #Melanoma #Immunoterapia #HDAcinibitori (translated)
Researchers from Porto and Minho have developed an innovative hydrogel composed of spherical nanocapsules and a polymer, which has the potential to treat melanoma, the most severe form of skin cancer, offering controlled drug release and possibly reducing the side effects associated with chemotherapy. #Hidrogel #Melanoma #Inovação (translated)
Il vaccino antitumorale a mRNA sviluppato da Moderna e Merck ha dimostrato di ridurre il rischio di recidiva e diffusione del melanoma nei pazienti ad alto rischio, segnando un importante passo avanti nell'immunoterapia oncologica. #Cancro #VaccinoMRNA #Immunoterapia
Il vaccino personalizzato a mRNA sviluppato da Moderna e Merck ha superato la fase 3, riducendo il rischio di recidiva e diffusione del melanoma, rappresentando un significativo progresso nella terapia oncologica. #melanoma #vaccino #immunoterapia
Mokslininkai Amerikoje sukūrė personalizuotą vakciną, kuri sumažina melanoma sergančių pacientų vėžio atsinaujinimo ir mirties riziką, tačiau tyrimai dar tęsiami. #vėžys #vakcina #melanoma
Farmacijos kompanijos „Moderna“ ir „Merck“ sėkmingai užbaigė didelio masto tyrimus dėl personalizuotos mRNR vakcinos nuo melanomos, kuri gali veiksmingai užkirsti kelią ligos atsinaujinimui ir metastazių plitimui. #onkologija #melanoma #vakcina
El entusiasmo por la vacuna personalizada de ARNm contra el melanoma de Moderna y MSD ha llevado a un notable aumento en la capitalización bursátil de la empresa, a pesar de que los resultados aún no se han presentado completamente y los expertos advierten sobre las limitaciones de su efectividad en otros tipos de cáncer. #VacunaContraElCáncer #Moderna #OncologíaPersonalizada
Personalizirano cepivo mRNA, razvito v sodelovanju podjetij Moderna in Merck, je doseglo pomemben preboj pri zdravljenju melanoma, saj po operaciji pomaga imunskemu sistemu prepoznati rakave celice in zmanjšuje tveganje za ponovitev bolezni, kar dokazuje uspešno zaključeno klinično preskušanje tretje faze. #CepivoProtiRaku #PersonaliziranoZdravljenje #mRNA
¿Una vacuna contra el melanoma? Qué hay realmente detrás del anuncio de MSD y Moderna https://t.co/8xFg5gHkHP #Vacuna #Melanoma #MSDModerna #Nocountrycodescanbeidentifiedinthetweetprovided.
Las farmacéuticas MSD y Moderna han anunciado resultados positivos de un ensayo clínico de una vacuna terapéutica personalizada que busca reducir el riesgo de recaída en pacientes con melanoma, aunque aún no han presentado detalles específicos sobre la eficacia de la terapia combinada con inmunoterapia, lo que ha disparado su valor en bolsa. #Cáncer #Vacunas #Investigación
